From Bench to Bedside: Immunotherapy for Prostate Cancer

Abstract EN

The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223.

However, immunotherapy has also emerged as an option for the treatment of this disease following the approval of sipuleucel-T by the FDA in 2010.

Immunotherapy is a rational approach for prostate cancer based on a body of evidence suggesting these cancers are inherently immunogenic and, most importantly, that immunological interventions can induce protective antitumour responses.

Various forms of immunotherapy are currently being explored clinically, with the most common being cancer vaccines (dendritic-cell, viral, and whole tumour cell-based) and immune checkpoint inhibition.

This review will discuss recent clinical developments of immune-based therapies for prostate cancer that have reached the phase III clinical trial stage.

A perspective of how immunotherapy could be best employed within current treatment regimes to achieve most clinical benefits is also provided.